A step forward for LRRK2 inhibitors in Parkinson's disease

Lewis, PA

Abstract

A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.

Citation

Lewis, P. (2022). A step forward for LRRK2 inhibitors in Parkinson's disease. Science Translational Medicine, 14(648), https://doi.org/10.1126/scitranslmed.abq7374

• Journal Article Type: Article
• Acceptance Date: May 25, 2022
• Publication Date: Jun 8, 2022
• Deposit Date: Jul 28, 2023
• Publicly Available Date: Aug 8, 2023
• Print ISSN: 1946-6234
• Publisher: American Association for the Advancement of Science
• Peer Reviewed: Peer Reviewed
• Volume: 14
• Issue: 648
• DOI: https://doi.org/10.1126/scitranslmed.abq7374
• Keywords: MUTATIONS